⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNGX News
Tango Therapeutics, Inc.
Form 8-K
sec.gov
TNGX
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
globenewswire.com
TNGX
Tango Therapeutics Announces Proposed $500 Million Public Offering
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
globenewswire.com
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX
Form 8-K
sec.gov
TNGX
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX